AR067746A1 - Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol - Google Patents

Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol

Info

Publication number
AR067746A1
AR067746A1 ARP080103306A ARP080103306A AR067746A1 AR 067746 A1 AR067746 A1 AR 067746A1 AR P080103306 A ARP080103306 A AR P080103306A AR P080103306 A ARP080103306 A AR P080103306A AR 067746 A1 AR067746 A1 AR 067746A1
Authority
AR
Argentina
Prior art keywords
clatrate
cyclodextrine
cilostazol
medicinal product
composite active
Prior art date
Application number
ARP080103306A
Other languages
English (en)
Inventor
Norio Okamoto
Yoshimasa Ito
Noriaki Nagai
Takuji Kurimoto
Tatsuya Yamashita
Yoshim Kawakami
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR067746A1 publication Critical patent/AR067746A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Un medicamento oftálmico para tratar glaucoma caracterizado porque comprende un derivado de carbostirilo de la formula general: (1) en donde A es un grupo alquileno inferior, R es un grupo cicloalquilo, el enlace entre las posiciones 3 y 4 el esqueleto carbostirilo es un enlace simple o un enlace doble, o una de sus sales; y una ciclodextrina. Reivindicacion 2: El medicamento de la reivindicacion 1 caracterizado porque el derivado de carbostirilo es 6-4-(1-ciclohexil-1H-tetrazol-5-il)butoxi]-3,4-dihidrocarbostirilo o una de sus sales.
ARP080103306A 2007-08-02 2008-07-30 Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol AR067746A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007202038 2007-08-02
JP2008050466 2008-02-29

Publications (1)

Publication Number Publication Date
AR067746A1 true AR067746A1 (es) 2009-10-21

Family

ID=39730869

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103306A AR067746A1 (es) 2007-08-02 2008-07-30 Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol

Country Status (12)

Country Link
US (1) US8686001B2 (es)
EP (1) EP2170332B1 (es)
JP (1) JP5236384B2 (es)
KR (1) KR20100051831A (es)
CN (1) CN101772345B (es)
AR (1) AR067746A1 (es)
AT (1) ATE538791T1 (es)
CA (1) CA2693364A1 (es)
ES (1) ES2376066T3 (es)
HK (1) HK1140421A1 (es)
TW (1) TWI428128B (es)
WO (1) WO2009017259A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012010415A1 (en) * 2010-07-22 2012-01-26 Merz Pharma Gmbh & Co. Kgaa Pharmaceutical composition containing a tryptophan derivative
ES2574832T3 (es) 2010-09-30 2016-06-22 Kyoto University Agente para el tratamiento de enfermedades oculares
TWI697337B (zh) 2013-08-07 2020-07-01 學校法人近畿大學 奈米粒子或奈米粒子組成物之製造方法，及支架或球囊導管之製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258084A (ja) * 1994-03-17 1995-10-09 Rohto Pharmaceut Co Ltd ジピリダモールを必須成分とする眼圧降下剤
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
TWI323660B (en) 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
US8569277B2 (en) * 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition

Also Published As

Publication number Publication date
TW200908975A (en) 2009-03-01
WO2009017259A1 (en) 2009-02-05
HK1140421A1 (en) 2010-10-15
CN101772345B (zh) 2012-12-26
TWI428128B (zh) 2014-03-01
ATE538791T1 (de) 2012-01-15
EP2170332B1 (en) 2011-12-28
KR20100051831A (ko) 2010-05-18
US8686001B2 (en) 2014-04-01
US20110212993A1 (en) 2011-09-01
CN101772345A (zh) 2010-07-07
EP2170332A1 (en) 2010-04-07
JP5236384B2 (ja) 2013-07-17
CA2693364A1 (en) 2009-02-05
JP2009227650A (ja) 2009-10-08
ES2376066T3 (es) 2012-03-08

Similar Documents

Publication Publication Date Title
AR066664A1 (es) Un medicamento para tratar enfermedad de alzheimer
CR20140537A (es) Compuesto heterocíclico nitrogenado
CY1122565T1 (el) Συνθεσεις και μεθοδοι μη χειρουργικης θεραπειας βλεφαροπτωσης
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
AR052179A1 (es) Mezcla sinergica con efecto insecticida y fungicida
CU24091B1 (es) Derivados de 2-(piridin-4-il)piridina o sales de los mismos como moduladores de proteína quinasa cdk9 y composiciones farmacéuticas que los comprenden
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
ECSP099552A (es) Compuestos triciclicos, composiciones y procedimientos
CO6511251A2 (es) Compuestos quimicos
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PE20130009A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
ES2376043T3 (es) Derivados de indazol para el tratamiento de enfermedades inducidas por hsp90.
CO6351691A2 (es) Combinacion de herbicidas con difluorometanosulfonilanilidas sustituidas con dimetoxitriazinilo
CR20120289A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
BR112015014507A2 (pt) composições pesticidas e processos relacionados a elas
BR112014004219A2 (pt) pirano[3,2-d][1,3]tiazol como inibidores de glicosidase
BR112012032399A2 (pt) embalagem de produtos de fumar
UY30835A1 (es) 8-alquinilxantinas y derivados
UY32502A (es) Agentes antihelmínticos y su utilización
AR090241A1 (es) INHIBIDORES DE LA b-SECRETASA
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
AR067446A1 (es) Un medicamento para tratar higado graso que comprende cilostazol
PE20141452A1 (es) Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmaceuticas que las usan
BR112012029009A2 (pt) formulações líquidas de fumarato de rupatadina
CL2017000231A1 (es) Arilhidrazidas que contienen una fracción de 2-piridona como agentes antibacterianos selectivos

Legal Events

Date Code Title Description
FB Suspension of granting procedure